Clinical Trials Logo

Kidney Failure, Chronic clinical trials

View clinical trials related to Kidney Failure, Chronic.

Filter by:

NCT ID: NCT04827290 Not yet recruiting - Clinical trials for Kidney Failure, Chronic

Assessment of the Effect of Restriction on Alimentary AGE in Progression of Chronic Kidney Disease

CKD AGE
Start date: August 1, 2024
Phase: N/A
Study type: Interventional

Normal-protein and low-AGE through raw or rare proteins diet versus normal-protein and high-AGE diet in stage IIIa-b renal failure patients

NCT ID: NCT04818151 Completed - Clinical trials for Kidney Failure, Chronic

Anticoagulation Strategies for Acute Venous Thromboembolism in Patients With End-Stage Renal Disease Using USRDS Data

Start date: January 1, 2021
Phase:
Study type: Observational

Patients with end stage renal disease (ESRD) are at significantly increased risk of thrombosis and bleeding relative to those with normal renal function which makes anticoagulation particularly challenging. Further, ESRD patients undergoing initiation of anticoagulation for acute VTE are often kept in the hospital for heparin "bridging" which may lead to a protracted length-of-stay (LOS) and may place patients at risk for hospital-associated complications. The advent of direct oral anticoagulants (DOACs) has offered physicians choices in the management of venous thromboembolism (VTE). However, evidence suggests that rivaroxaban and dabigatran are associated with a higher risk of bleeding in ESRD patients. In contrast, research suggests that apixaban may be safer in patients with ESRD, and recent evidence suggests lower bleeding rates in ESRD patients treated for atrial fibrillation with apixaban compared to those treated with warfarin. However, to date, no large national cohort studies have examined the safety, effectiveness, and healthcare utilization of apixaban in patients with ESRD who have acute VTE. The investigators propose to use the Standard Analytic Files from the United States Renal Data System (USRDS) for years 2014 through 2018 to evaluate the safety, effectiveness, and healthcare utilization of ESRD patients initiated on apixaban compared to those initiated on warfarin (following heparin) to treat acute VTE.

NCT ID: NCT04797195 Completed - Clinical trials for Kidney Failure, Chronic

Improving Care for Peritoneal Dialysis Patients With the CKD-PD App

Start date: December 13, 2021
Phase: N/A
Study type: Interventional

Managing the hydration status in patients undergoing peritoneal dialysis (PD) is a key task for nephrologists in Thailand that is made difficult due to lack of timely access to hydration metrics including weight, blood pressure, and ultrafiltration volume. This research project aims to improve the monitoring of hydration status in PD patients from a bimonthly, in-clinic review of a handwritten log-book to a smart phone based app (CKD-PD) with digitized data that allows for near real time monitoring hydration abnormalities, thereby creating the opportunity for earlier treatment of overhydration. The investigators hypothesize that use of the CKD-PD will improve early treatment of overhydration, and potentially reduce the incidence of complications, hospitalizations, and mortality in PD patients.

NCT ID: NCT04796558 Active, not recruiting - Kidney Failure Clinical Trials

Validation of Arterio Venous Access Stage (AVAS) Classification

VAVASC
Start date: April 1, 2021
Phase:
Study type: Observational [Patient Registry]

VAVASC trial is an observational multicentre study. The aim of this trial is to validate AVAS (arteriovenous vascular access stage) classification. The classification is used for determining which type of access is the most suitable for the patient on the basis of the patient´s vascular anatomy The methodology of this trial is to apply AVAS classification on patients who are indicated for creation of vascular access for hemodialysis. Data on these patients (vascular anatomy status, AVAS type, and predicted type of arterio venous access, demographic data etc.) will be than statistically analysed. Patients will then undergo creation of the selected arteriovenous access. They will be observed in terms of the access functionality. The follow up will be 1 to 3 years. The second aim of this study is to evaluate the relationship between AVAS classification and uninterrupted use of the created arterio venous access.

NCT ID: NCT04714853 Recruiting - Kidney Failure Clinical Trials

Different Dialysis Modalities and Diet on Gastrointestinal Biome and Azotaemic Toxins

Start date: October 2015
Phase:
Study type: Observational

. This is a prospective observational pilot study to analyse gastrointestinal tract bacterial populations in peritoneal dialysis and haemodialysis patients under the care of the Royal Free Hospital with chronic kidney disease who have been established on regular haemodialysis and peritoneal dialysis treatments in a Royal Free Hospital kidney care centre.

NCT ID: NCT04671771 Recruiting - Kidney Failure Clinical Trials

A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access

Start date: December 3, 2020
Phase: N/A
Study type: Interventional

The CSP-2002 study will evaluate the safety and effectiveness of the InnAVasc arteriovenous graft (AVG) when implanted in and used for hemodialysis in participants suffering from end-stage renal failure (ESRD). The InnAVasc AVG is implanted and used similar to other standard-of-care dialysis grafts currently on the market. However, the InnAVasc AVG has been uniquely designed to potentially allow for immediate needle access (same day as implant surgery as opposed to 2-4 weeks of waiting), to potentially reduce excessive bleeding from the graft after dialysis, and it may provide protection from improper or missed needle cannulation attempts.

NCT ID: NCT04660383 Not yet recruiting - Clinical trials for Kidney Failure, Chronic

Intradialytic Inspiratory Muscle Training at Different Intensities and Functional Capacity

Start date: December 2022
Phase: N/A
Study type: Interventional

Investigate the effects of Inspiratory Muscle Training (IMT) performed during hemodialysis (HD) procedures in patients with end stage kidney disease (ESKD). With intervention of thirty-six IMT sessions, performed three times a week, at an intensity of 50%, 30% and 10% (sham) of the maximum inspiratory pressure (MIP).

NCT ID: NCT04641650 Completed - Diabetes Clinical Trials

Pilot Study : FreeStyle Libre Pro Flash Continuous Glucose Monitoring System in Subjects With Diabetes on HemoDIALsis

FSL DIAL
Start date: July 21, 2021
Phase:
Study type: Observational

Continuous monitoring of glucose with a FreeStyle Libre pro sensor in diabetic and dialysis patients

NCT ID: NCT04626427 Terminated - Clinical trials for Chronic Kidney Diseases

The WavelinQ™ Arterio-Venous Endovascular Fistula: A Global, Post-Market Investigation

WAVE-Global
Start date: December 22, 2020
Phase: N/A
Study type: Interventional

This is a global, multi-center, prospective, post-market, confirmatory, interventional, non-randomized, single-arm clinical investigation evaluating arteriovenous fistula (AVF) creation by means of the WavelinQ™ EndoAVF System in patients who require a vascular access for hemodialysis (HD).

NCT ID: NCT04610593 Completed - Clinical trials for Chronic Kidney Diseases

Effects of a Mindfulness-based Intervention in Stress, Pain and Quality of Life in People Undergoing Hemodialysis

Start date: May 6, 2019
Phase: N/A
Study type: Interventional

This project has as main objective to evaluate the effects of a Mindfulness-based intervention (MBI) in the reduction of stressors, pain and quality of life of people with chronic kidney disease undergoing hemodialysis (HD). The investigators hypothesize that this program offered during hemodialysis sessions may modify the pain profile, stressors levels and may improve the quality of life by the people in hemodialysis. This is an incipient field of research at the international level and almost nonexistent in Brazil. Evidence indicates the need for MBIs to be performed during HD sessions, adapted to the context, to facilitate patient compliance, contribute to the management of the discomfort generated during HD and promote health.